



## **Coronavirus Funding Opportunity Announcements**

*Released by the GCO 4/1 - 4/15/2020*

- [Coronavirus \(4/1/20\)](#)
- [Coronavirus \(4/2/20\)](#)
- [Coronavirus \(4/5/20\)](#)
- [Coronavirus \(4/6/20\)](#)
- [Coronavirus \(4/7/20\)](#)
- [Coronavirus \(4/9/20\)](#)
- [Coronavirus \(4/10/20\)](#)
- [Coronavirus \(4/13/20\)](#)
- [Coronavirus \(4/14/20\)](#)
- [Coronavirus \(4/15/20\)](#)

From: [research.listserv@mscm.edu](mailto:research.listserv@mscm.edu)  
 Subject: [GCO] COVID-19 Funding Opportunities (4/1/20)  
 Date: Wednesday, April 1, 2020 5:46:29 AM  
 Attachments: Funding02.PNG  
 InfoF1.png

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN and other sources. Please note that some opportunities have rapidly approaching deadlines.

Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date
091391	RFP --Prototype Development to Combat Novel Coronavirus Disease COVID-19	Department of the Army	MTEC-Presolicitation-NETCCN-COVID-19	30-Apr-2020
067721	Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)	National Center for Advancing Translational Sciences/NIH/DHHS	PAR-18-332	05-Jun-2020
069930	Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)	National Center for Advancing Translational Sciences/NIH/DHHS	PAR-18-462	16-Jun-2020
065911	Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)	National Center for Advancing Translational Sciences/NIH/DHHS	PAR-17-465	26-Jun-2020

### Other Sources

NSF-BSF COVID-19 Rapid Submission	National Science Foundation- United States Israel Binational Science Foundation	Continuous Submission	<a href="https://www.bsf.org.il/funding-opportunities/nsf-bsf-joint-research-grants/the-programs/">https://www.bsf.org.il/funding-opportunities/nsf-bsf-joint-research-grants/the-programs/</a>
-----------------------------------	---	-----------------------	---

SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091391 <sup>19</sup>	<a href="#">RFP --Prototype Development to Combat Novel Coronavirus Disease COVID-19</a>	Department of the Army	MTEC-Presolicitation-NETCCN-COVID-19	30-Apr-2020	Not Available

Contact Name  
 Contact Telephone  
 Contact Email  
 Sponsor Website  
 Deadline Dates (ALL)

Randall Fernanders  
 843-760-3378  
[randall.fernanders@ati.org](mailto:randall.fernanders@ati.org)  
<https://beta.sam.gov/opp/245ccb8f39a4423ab26468225e5e788c/view>  
 30-Apr-2020

The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a Request for Project Proposals (RPP) to rapidly develop and deploy the National Emergency Telecritical Care Network (NETCCN) - a cloud-based, low-resource, stand-alone health information management system for the creation and coordination of flexible and extendable "virtual critical care wards." These high acuity, virtual wards would bring high-quality critical care capability to nearly every bedside, be it healthcare facility, field hospital, or gymnasium.

#### PROGRAM BACKGROUND:

This program is specifically focused on preparation for COVID-19 related critical care capability shortages. Although the United States has more critical care beds per capita than other developed nations, emerging national and international experience with COVID-19-related critical illness suggests a high level of oncoming system stress on critical care resources and a likely potential for intensive care unit (ICU) beds and care teams to be overwhelmed.

Tele-critical care can be a powerful force-multiplier in the extension of limited critical care resources in both high-census urban centers and rural communities in which access to critical care – facilities, equipment and trained clinicians - is limited even under normal conditions. Many local and regional health systems have invested extensively in telemedicine capabilities, but many of these systems lack sufficient scalability, are limited both in interoperability with other telehealth systems and scope and reach of partner provider-networks and supported tele-clinical services.

The vision for this program is to extend local tele-critical care capability sets to a broader, flexible network - first locally, then step-wise regionally and nationally - that can be leveraged wherever there is need.

#### SOLUTION REQUIREMENTS:

This upcoming RPP will focus on enhanced development of integrated technologies and clinical workflows to establish and rapidly scale virtual wards. The program will support the extension of high-quality intensive care to traditional (e.g. critical access hospitals and clinics) and non-traditional and temporary healthcare facilities (e.g. field hospitals and gymnasiums) which lack adequate critical care expertise and resources necessary for care of COVID-19-related illnesses. Enhanced white papers should specifically address providing EXISTING technologies available for other use cases that can be rapidly adapted to establishing a National Emergency Tele Critical Care Network (NETCCN). Existing technologies which should be included are as follows:

Synopsis

- Mobile communications capabilities including synchronous audio/video, asynchronous messaging, and access to continuous monitoring
- Clinician-facing web portal and/or mobile-based application (goal is availability on every device)
- Capability for basic documentation in real-time as well as data collection and reporting
- Cloud-based information storage including ability for later offloading via PDF or HL7
- Specific requirements for the creation of these "virtual wards" (i.e., cohorts of patients that are managed together and with continuity by the tele critical care [TCC] teams) include the following:

- Self-contained health information management system (or system of systems) using elastic cloud computing at a minimum, IoT connections, and anticipated incorporation of future AI to enable:
- Patient flow management

Patient level information management  
 Continuity of care through shift change, provider turnover, and patient transfer using lightweight patient hand-off tools.  
 Integrated audio-visual communications capability  
 Information sharing and reporting capabilities:  
 A governance structure or "network of networks" must be implemented to coordinate this response  
 Reporting and data visualization tools of both patient and system level data are crucial for information sharing, dissemination of consensus best-practice recommendations, measures of system stress, and rapid reallocation of resources.  
 Survey capabilities – of patients/caregivers, local clinicians, and remote TCC experts should – should be included.  
 Patient-level data should be aggregated and stored for later analysis, can eventually be batch loaded into existing EMRs when resources allow  
 System should allow for alerts, bulletins, and other timely communications to be pushed out to users  
 Integrated information sharing  
 Coverage/staffing/care team model(s) for virtual wards to include tiered staffing concepts with local proceduralists (as available) supported by the technology solution developed in this proposal and serviced by tele critical care clinicians.  
 The system will need to include a method to verify credentials of tele critical care clinicians/teams who participate as service providers.

06772) [Clinic Testing Therapeutic/Indication Pairing Strategies \(U01 Clinical Trial Required\)](#) National Center for Advancing Translational Sciences/NIH/DHHS PAR-18-332 05-Jun-2020 9,000,000.00 USD  
 Contact Name Bobbie Ann Austin, Ph.D.  
 Contact Telephone 301-435-0824  
 Contact Email [Bobbie.Austin@nih.gov](mailto:Bobbie.Austin@nih.gov)  
 Program URL <https://grants.nih.gov/grants/guide/pa-files/PAR-18-332.html>  
 Deadline Dates (ALL) 05-Jun-2020, 05-Oct-2020

Synopsis National Center for Advancing Translational Sciences (NCATS) invites applications for clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., <http://www.ncats.nih.gov/ntu/therapeutics/current>, <http://openinnovation.astrazeneca.com>, or any website that lists experimental drugs or biologics), or computational algorithms. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

06993) [Clinical Trial Planning: Therapeutic/Indication Pairing Strategies \(U34 Clinical Trial Not Allowed\)](#) National Center for Advancing Translational Sciences/NIH/DHHS PAR-18-462 16-Jun-2020 225,000.00 USD  
 Contact Name Bobbie Ann Austin, Ph.D.  
 Contact Telephone 301-435-0824  
 Contact Email [Bobbie.Austin@nih.gov](mailto:Bobbie.Austin@nih.gov)  
 Program URL <https://grants.nih.gov/grants/guide/pa-files/PAR-18-462.html>  
 Deadline Dates (ALL) 16-Jun-2020, 16-Oct-2020

Synopsis National Center for Advancing Translational Sciences (NCATS) invites applications to support clinical trial planning. This includes collection of feasibility data and complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. The clinical trial that is being planned must aim to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time a clinical trial planning award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., <http://www.ncats.nih.gov/ntu/therapeutics/current>, <http://openinnovation.astrazeneca.com>, or any website that lists experimental drugs or biologics), or computational algorithms. This program will use the NIH U34 Planning Cooperative Agreement grant mechanism.

06591) [Bench Testing Therapeutic/Indication Pairing Strategies \(UG3/UH3\)](#) National Center for Advancing Translational Sciences/NIH/DHHS PAR-17-465 26-Jun-2020 700,000.00 USD  
 Contact Name Bobbie Ann Austin, Ph.D.  
 Contact Telephone 301-435-0824  
 Contact Email [Bobbie.Austin@nih.gov](mailto:Bobbie.Austin@nih.gov)  
 Program URL <https://grants.nih.gov/grants/guide/pa-files/PAR-17-465.html>  
 Deadline Dates (ALL) 26-Jun-2020

Synopsis National Center for Advancing Translational Sciences (NCATS) invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase I trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., <http://www.ncats.nih.gov/ntu/assets/current>, <http://openinnovation.astrazeneca.com>, or any website that lists experimental therapies), or use of computational algorithms. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning; this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

SMARTS™ funding alerts are a service of [InfoEd Global's](#) SPIN™ funding opportunities.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (4/2/20)  
**Date:** Thursday, April 2, 2020 8:32:00 AM  
**Attachments:** [Funding02.PNG](#)  
[InfoEd.png](#)

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN. Please note that some opportunities have rapidly approaching deadlines.

Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091624	<a href="#">Open Call for Innovation Focus Area: COVID-19: Rapid Sanitising Technology</a>	Defence and Security Accelerator (DASA)	IFA019	None posted	Not Available
Contact Email	<a href="mailto:accelerator@dstl.gov.uk">accelerator@dstl.gov.uk</a>				
Sponsor Website	<a href="https://www.gov.uk/government/organisations/defence-and-security-accelerator">https://www.gov.uk/government/organisations/defence-and-security-accelerator</a>				
Program URL	<a href="https://www.gov.uk/government/publications/defence-and-security-accelerator-dasa-open-call-for-innovation">https://www.gov.uk/government/publications/defence-and-security-accelerator-dasa-open-call-for-innovation</a>				

In addition to its regular Open Call, DASA publishes Open Call innovation focus areas to increase awareness of some of the enduring

challenges faced by defence and security stakeholders, and to stimulate the submission of relevant innovative proposals.

Synopsis

For the current focus area: COVID-19: Rapid Sanitising Technology, DASA is looking to identify, develop and demonstrate rapid sanitising technologies for ambulances that have transported a patient with suspected COVID-19.

091618	<a href="#">TechWatch Meeting Request</a>	Biomedical Advanced Research and Development Authority/ASPR/DHHS	None posted	Not Available
--------	---	--	-------------	---------------

Contact Email

[techwatchinbox@hhs.gov](mailto:techwatchinbox@hhs.gov)

Sponsor Website

<https://www.medicalcountermeasures.gov/>

Program URL

<https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/>

Synopsis

The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.

SMARTS™ funding alerts are a service of [InfoEd Global](#)'s SPIN™ funding opportunities.

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (4/5/20)  
Sunday, April 5, 2020 9:55:53 AM  
**Date:** [Funding02.PNG](#)  
**Attachments:** [InfoEd.png](#)

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN and the latest NIH Guide, which includes notices of additional Institutes/Centers participating in the administrative supplements related to COVID-19.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office

### **Weekly NIH Funding Opportunities and Notices for April 03, 2020**

#### **Notice of Changes to Funding Opportunities**

- [Notice of National Cancer Institute \(NCI\) Participation in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements \(Urgent Supplement - Clinical Trial Optional\)](#)  
(NOT-CA-20-048)  
National Cancer Institute
- [Notice of NIDCD's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements \(Urgent Supplement - Clinical Trial Optional\)"](#)  
(NOT-DC-20-003)  
National Institute on Deafness and Other Communication Disorders

[Notice of NHGRIs Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements \(Urgent Supplement - Clinical Trial Optional\)"](#)

(NOT-HG-20-034)

National Human Genome Research Institute

- [Notice of Participation of the National Institute on Minority Health and Health Disparities \(NIMHD\) in PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements \(Urgent Supplement - Clinical Trial Optional\)](#)

(NOT-MD-20-018)

National Institute on Minority Health and Health Disparities

- [Notice of NCATS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements \(Urgent Supplement - Clinical Trial Optional\)"](#)

(NOT-TR-20-015)

National Center for Advancing Translational Sciences

### Notices of Special Interest

- [Notice of Special Interest \(NOSI\): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-AG-20-022)

National Institute on Aging

National Institute of Mental Health

- [Notice of Special Interest \(NOSI\) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus](#)

(NOT-HG-20-030)

National Human Genome Research Institute



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
078383	<a href="#">NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-052	07-May-2020	100,000.00 USD
Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>				
Program URL	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-052.html">https://grants.nih.gov/grants/guide/pa-files/PA-19-052.html</a>				
Deadline Dates (ALL)	07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021, 16-Oct-2021, 07-Jan-2022				
Synopsis	The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small,				

self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

091706 [RFI -- AMENDMENT -- Collection of Serum Samples from Patients Infected With SARS-CoV-2](#) Department of Health & Human Services 2020-0001-COV19-EDS 06-Apr-2020 Not Available

Contact Name Eric Sullivan, Contracting Officer  
 Contact Telephone 412-386-5290  
 Contact Email [LRV4@cdc.gov](mailto:LRV4@cdc.gov)  
 Program URL <https://beta.sam.gov/opp/7042029f6159423a81c4528112293675/view>  
 Deadline Dates (ALL) 06-Apr-2020

Title: Request for Information – Collection of Serum Samples from Patients Infected With SARS-CoV-2 Synopsis: This is a request for information. It is not a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to: Determine the level of interest which exists in the open market for providing the needed services; Obtain information, needs, capabilities, constraints, capacities, and requirements of those potential providers of the needed service; and Make use of this information to inform potential acquisition strategies that may be used to support a) emergency public health response activities, b) on-going assay development, and c) research. Background: The Centers for Disease Control and Prevention (CDC) is a public health organization that operates within the Department of Health and Human Services. The CDC requires access to freshly drawn whole blood, blood products, and other unique sample types and materials to enable rapid assay development during infectious disease outbreaks. In addition to CDC, many commercial manufacturers and research laboratories are developing serological tests for diagnostic purposes in response to the COVID-19 pandemic. Fundamental to the development and implementation of serologic procedures, and the evaluation of these procedures, is the availability of positive control samples (i.e., serum or plasma from patients with well-documented, laboratory-confirmed disease). The only source of positive control samples for assays for human samples originates from individuals who have had recent COVID-19 illnesses. Traditionally, positive controls for serologic test procedures are identified from patient samples submitted to the CDC laboratory for routine diagnostic testing. However, these samples are typically small volume (1 ml or less) and cannot serve as standardized controls. Similarly, uniform panels of positive control serum are generally unavailable, limiting the ability of CDC and other laboratories to standardize and calibrate their assays. Requirement: CDC is seeking information from companies and other organizations about their capability and capacity to deploy to the site of a domestic SARS-CoV-2 outbreak, obtain informed consent, collect whole blood specimens (~20 ml) from individuals infected with SARS-CoV-2 who are at least 14-28 days after the onset of symptoms, and safely ship these specimens to CDC in accordance with all applicable local, state,



## Synopsis

and federal and/or international laws, and regulations. Additionally, the agency is seeking information on the following: To obtain information, needs, capabilities, constraints, capacities, and requirements of those vendors and companies who do have an interest (or potential interest) in providing the needed services; Information provided should include: Name, location and size of company Service and/or coverage area (e.g. throughout the United States and/or internationally). Description of sites used to collect patient samples. Availability of IRB and ability to develop IRB approved protocols and consent documents. Ability to explain the reason for the sample collection and the informed consent document to prospective patients, obtain consent, and transfer the consent documents to CDC. Ability to obtain required patient meta data (age, gender, results of clinical testing, etc), complete the required sample data forms, and securely transmit the information to CDC. Ability to safely collect whole blood and prepare serum prior to shipment to CDC. Description of safety measures used for blood collection. Ability to perform testing to determine the titer of antibodies against SARS-CoV-2 Current ability to collect, and details of prior experience collecting, specimens from patients in a medical setting (e.g., hospital, clinic, physician office) and/or in patient's homes or other locations. Information about time it would take to deploy personnel to the site of the outbreak and begin collecting samples. Methods of sample transport and shipping which may be utilized, and measures to assure shipping conditions, such as temperature, to preserve sample integrity. Ability to track items in transit and provide exact locations of samples at all times Ability to adhere to all applicable hazardous materials transportation regulations Any liability issues, constraints and/or concerns to be considered Submission Instructions: Respondents are asked to provide only the most pertinent information, data, and materials necessary to adequately convey a declaration of capability in line with this notice. Respondents are asked to provide a cover page that contains the following information: All Point of Contact information (email addresses, phone numbers, and mailing address) DUNS number All relevant NAICS Codes Identification as a large or small business. If small, indicate the classification. Identification of services on any Federal Supply Schedules, if any, and the relevant schedule numbers. Proprietary information, if any, should be minimized and **MUST BE CLEARLY MARKED**. To aid HHS, please segregate and clearly mark proprietary information. Please be advised that all submissions become the property of the Government and will not be returned. This **REQUEST FOR INFORMATION** is in accordance with FAR 52.215-3 Request for Information or Solicitation for Planning Purposes (Oct 1997), as such, any information received will be for the purpose of planning only. Responses to this **REQUEST FOR INFORMATION** notice, along with a firm's capability statement referencing "Request for Information – Serum from COVID-19 Patients" may be submitted electronically via email to the points of contact listed below **NO**

LATER THAN 5PM EST on 6 April 2020. Point of Contact: Eric Sullivan, Contracting Officer [LRV4@CDC.GOV](mailto:LRV4@CDC.GOV) (412) 386-5290. Additional [beta.sam.gov](http://beta.sam.gov) information Notice Id eca61738662846dd90b6a3bd095fa9d3 Source <https://beta.sam.gov/opp/eca61738662846dd90b6a3bd095fa9d3/view>.

Note: This link might not be valid after archive date below.

	Archive Date			
	4/21/2020			
091851	<a href="#">Global Health Security Partner Enhancement: Expanding Efforts and Strategies to Protect and Improve Public Health in Senegal</a>	Center for Global Health/CDC/DHHS	CDC- RFA- GH20-2117	02-Jun-2020 5,000,000.00 USD
Contact Name	Jim Ting, Project Office			
Contact Telephone	+221 777 408 878			
Contact Email	<a href="mailto:Jyu8@cdc.gov">Jyu8@cdc.gov</a>			
Program URL	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=326003">https://www.grants.gov/web/grants/view-opportunity.html?oppId=326003</a>			
Deadline Dates (ALL)	02-Jun-2020			
Synopsis	<p>The 2014 Ebola outbreak has highlighted the importance of international preparedness and coordinated epidemic response efforts across borders and within countries to properly address public health emergencies of international concern. In support of the CDC's global health security responsibilities, this funding opportunity will contribute to two priority strategies in Senegal: (1) strengthening surveillance system for Antimicrobial Resistance (AMR) threat and (2) strengthening national laboratory systems and biosafety and security to respond to public health emergencies. The key strategy-specific activities to be employed include (1) increase geographic coverage and expand maximum load of the specimen referral network; (2) Improvement of biosecurity of medical laboratories (3) Strengthening of laboratory equipment management, (4) improvement of access to and participation in national and international quality assurance programs and proficiency testing; (5) strengthening AMR surveillance system.</p>			

SMARTS™ funding alerts are a service of [InfoEd Global](#)'s SPIN™ funding opportunities

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.



From: [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
 Subject: [GCO] COVID-19 Funding Opportunities (4/6/20)  
 Monday, April 6, 2020 2:19:59 PM  
 Date: [Funding02.PNG](#)  
 Attachments: [InfoEd.png](#)

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091865	<a href="#">Newton Award for Transformative Ideas During the COVID-19 Pandemic</a>	Department of Defense	BRO-20-NEWTON	15-May-2020	Not Available

Contact Name: Jonathan Becker  
 Contact Email: [jonathan.l.becker2.civ@mail.mil](mailto:jonathan.l.becker2.civ@mail.mil)  
 Program URL: <https://www.grants.gov/web/grants/view-opportunity.html?oppId=326034>

Deadline Dates (ALL) 15-May-2020  
 From 1665 to 1666, the Great Plague of London swept across England, likely taking the lives of over 100,000 people (United Kingdom Public Archives, 2020). Though the germ theory of disease would not be formulated until the 1860s, the English public engaged in “social distancing” behaviors to avoid illness (Washington Post, 2020),

## Synopsis

leading to the closure of universities. Among the displaced was a young Isaac Newton, still a student at Trinity College in Cambridge. During the ensuing year of isolated study and reflection, Newton developed the basis for calculus, as well as foundational theories in gravitation, motion, and optics.

Separated from the Great Plague by 350 years, the COVID-19 pandemic has led to similar health responses among the general public and scientific community, forcing the closure of laboratories and universities throughout the world and slowing scientific progress across theoretical and empirical domains. To help stimulate scientific thought and encourage efforts and advancements in the spirit of Sir Isaac, the Basic Research Office in the U.S. Department of Defense (DoD) announces the Newton Award for Transformative Ideas during the COVID-19 Pandemic.

SMARTS™ funding alerts are a service of [InfoEd Global](#)'s SPIN™ funding opportunities

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (4/7/20)  
**Date:** Tuesday, April 7, 2020 2:10:35 PM  
**Attachments:** [Funding02.PNG](#)  
[InfoEd.png](#)

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092022	<a href="#">Fast-Track Grant For Research on Non-Animal Approaches to Investigate Mechanisms, Medicines, and Vaccines for Coronaviruses</a>	Johns Hopkins Bloomberg School of Public Health	N/A	30-Apr-2020	40,000.00 USD

Contact Name

Camila Januario

Contact Email

[cjanuar1@jhu.edu](mailto:cjanuar1@jhu.edu)

Program URL

<https://caat.jhsph.edu/programs/grants/covid19.html>

Deadline Dates (ALL)

30-Apr-2020

In response to the global COVID-19 pandemic, the Johns Hopkins Center for Alternatives to Animal Testing (CAAT) at the Bloomberg School of Public Health is redirecting part of our grant program to help accelerate the discovery of mechanisms, medicines, and vaccines for

Synopsis

COVID-19.

The program's goal is to centralize information and stimulate funding of the development of non-animal, human biology-based models to help coordinate and accelerate response to current and emerging pandemics.

SMARTS™ funding alerts are a service of [InfoEd Global](#)'s SPIN™ funding opportunities

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (4/9/20)  
Thursday, April 9, 2020 4:26:20 PM  
**Date:** [Funding02.PNG](#)  
**Attachments:** [InfoEd.png](#)

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092104	<a href="#">AI 4 COVID-19: Data Science and Artificial Intelligence in the Public Administration to Strengthen the Fight Against COVID-19 and Future Pandemics - 2020</a>	Foundation for Science and Technology	N/A	28-May-2020	259,200.00 USD

Contact Name: Av. D. Carlos  
Contact Email: [concursoprojetos@fct.pt](mailto:concursoprojetos@fct.pt)  
Program URL: <https://www.fct.pt/apoios/projectos/concursos/datascience/index.phtml.en>  
Deadline Dates (ALL): 28-May-2020  
Fundação para a Ciência e Tecnologia (FCT) is launching a new



Synopsis

competition aimed at data processing within the current pandemic of the new coronavirus SARS CoV2 and the disease COVID-19 and in the context of the situation of increasing uncertainty and social alarm in which we live. The objective is to support R&D projects and initiatives that can contribute to new responses to this and future pandemics, with an emphasis on supporting citizens and health care services.

SMARTS™ funding alerts are a service of [InfoEd Global](#)'s SPIN™ funding opportunities

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Special Interest Funding Opportunities from the NIH  
Friday, April 10, 2020 4:11:17 PM  
**Date:** [Funding02.PNG](#)  
**Attachments:**

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 special interest funding opportunities from the NIH. Please note that some opportunities have rapidly approaching deadlines. So please check the notice carefully.

Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

The Grants and Contracts Office

Notices of Special Interest

- [Notice of Special Interest \(NOSI\): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 \(COVID-19\)](#)  
(NOT-AT-20-011)  
National Center for Complementary and Integrative Health  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism
- [Notice of Special Interest \(NOSI\): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 \(COVID-19\)](#)  
(NOT-CA-20-042)  
National Cancer Institute
- [Notice of Special Interest \(NOSI\): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 \(COVID-19\)](#)  
(NOT-CA-20-043)  
National Cancer Institute
- [Notice of Special Interest \(NOSI\) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-DC-20-004)

National Institute on Deafness and Other Communication Disorders

- [Notice of Special Interest \(NOSI\): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 \(COVID-19\) within the Mission of NIDDK](#)

(NOT-DK-20-018)

National Institute of Diabetes and Digestive and Kidney Diseases

- [Notice of Special Interest \(NOSI\): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 \(COVID-19\) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission](#)

(NOT-DK-20-020)

National Institute of Diabetes and Digestive and Kidney Diseases

- [Notice of Special Interest \(NOSI\): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-EB-20-006)

National Institute of Biomedical Imaging and Bioengineering

- [Notice of Special Interest \(NOSI\): Development of Biomedical Technologies for Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-EB-20-007)

National Institute of Biomedical Imaging and Bioengineering

- [Notice of Special Interest \(NOSI\): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-EB-20-008)

National Institute of Biomedical Imaging and Bioengineering

- [Notice of Special Interest \(NOSI\): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 \(COVID-19\)](#)

(NOT-ES-20-015)

National Institute of Environmental Health Sciences

- [NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training \(Admin Supp Clinical Trial Not Allowed\)](#)

(NOT-ES-20-017)

National Institute of Environmental Health Sciences

- [Notice of Special Interest \(NOSI\): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19](#)

(NOT-GM-20-027)

National Institute of General Medical Sciences

- [Notice of Special Interest \(NOSI\): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities](#)

(NOT-MD-20-019)

National Institute on Minority Health and Health Disparities

National Institute on Aging

National Institute of Mental Health

- [Notice of Special Interest \(NOSI\) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus](#)

(NOT-MH-20-047)

National Institute of Mental Health

National Institute on Aging

National Institute on Alcohol Abuse and Alcoholism

National Institute on Minority Health and Health Disparities

Office of Disease Prevention

- [Notice of Special Interest \(NOSI\) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus](#)

(NOT-TR-20-016)

National Center for Advancing Translational Sciences

- [Notice of Special Interest \(NOSI\) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus](#)

(NOT-TR-20-017)

National Center for Advancing Translational Sciences

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.

From: [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
 Subject: [GCO] COVID-19 Funding Opportunities (4/13/20)  
 Date: Monday, April 13, 2020 10:49:14 AM  
 Attachments: [Funding02.PNG](#)  
[InfoEd.png](#)

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092488	<a href="https://www.dla.mil/HQ/InformationOperations/Accelerate/">https://www.dla.mil/HQ/InformationOperations/Accelerate/</a>	Defense Logistics Agency	N/A	04-May-2020	Not Available [LOI/Pre-App]
Contact Email	<a href="mailto:accelerate@dla.mil">accelerate@dla.mil</a>				
Program URL	<a href="https://www.fct.pt/apoios/projectos/concursos/datascience/index.phtml.en">https://www.fct.pt/apoios/projectos/concursos/datascience/index.phtml.en</a>				
Deadline Dates (ALL)	04-May-2020 [LOI/Pre-App]				
Synopsis	DLA seeks novel solutions to combat COVID-19. Specifically, the DoD suffers from an increasing demand for Personal Protective Equipment ("PPE") for individuals who perform critical national security functions. Of particular concern are N95 masks, which are primarily produced overseas. Overseas production is compounded by a lag in domestic production. Domestic production is limited because of the unavailability of mask conversion machines, long timelines to manufacture and assemble new production lines and limited supplies of refined materials. Moreover, various state governments are competing to buy the limited N95s currently available, reducing supply and increasing cost. DLA seeks prototype solutions that can help combat this shortage in the near and medium term.				

SMARTS™ funding alerts are a service of [InfoEd Global's](#) SPIN™ funding opportunities

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.  
[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (4/14/20)  
Tuesday, April 14, 2020 9:42:42 AM  
**Date:** [Funding02.PNG](#)  
**Attachments:** [InfoEd.png](#)

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



[RFP -- AMENDMENT -- Special Notice for Innovative Commercial Products In Support of CORONAVIRUS \(COVID-19\) Response](#) Department of Homeland Security CSOP-HQ-CV-20-00001 31-Aug-2020 Not Available

Contact Email [COVID19CSOP@HQ.DHS.GOV](mailto:COVID19CSOP@HQ.DHS.GOV)  
Program URL <https://beta.sam.gov/opp/4f00c495f2eb489b8297295bb651bbee/view>  
Deadline Dates (ALL) 31-Aug-2020

Special Notice for Innovative Commercial Products In Support of CORONAVIRUS (COVID-19) Response The Department of Homeland Security (DHS), Office of Procurement Operations (OPO) in support of Office of the Chief Procurement Officer will use the Commercial Solutions Opening Pilot Program (CSOP) procedures to acquire innovative, commercial items, technologies and services currently in the production/commercialization phase as well as

## Synopsis

adaptations of existing commercial products. The DHS Commercial Solutions Opening Pilot Program (CSOP) is a non-Federal Acquisition Regulation (FAR) based solicitation authority for acquiring innovative and commercial solutions. Section 880 of the National Defense Authorization Act (NDAA) for Fiscal Year 2017 (Pub. L. 114-328) authorized DHS to implement a pilot program to competitively procure innovative commercial items, technologies, and services using commercial solution opening procedures. CSOP is a new acquisition mechanism that provides a streamlined acquisition process and simplified contract terms that is designed to maximize efficiency and economy and minimize burdens and administrative costs for both the Government and industry. The Department of Homeland Security (DHS) efforts in preparedness and readiness have facilitated a speedy, whole-of-government response in confronting COVID-19, keeping Americans safe, and helping detect and slow the spread of the virus. DHS is seeking innovative commercial products that are in support of the COVID-19 response or similar microbial threats. Considering the magnitude and potential threat that COVID-19 and similar microbial threats pose to our nation's health, safety and security, the Government seeks to rapidly accelerate the testing and fielding of new capabilities, employing innovative commercial products to the detection of exposure, prevention, containment and treatment of COVID-19 and similar microbial threats. Such innovative commercial products would be in support of the mission of the DHS, including the assistance that the FEMA is providing, in coordination with the HHS, to state, local, tribal, territorial governments and other eligible entities under the Stafford Act. Proposed innovative commercial products may be, but are not limited to, products that: 1) supplement shortages and/or emerging needs for personal protective equipment, 2) enhance or expedite screening capabilities, 3) enhance or expedite facility cleaning capabilities, 3) extend testing capabilities, 4) utilize technology to support the COVID-19 response, or 5) convert existing production and logistics operations to support the COVID-19 response. An important aspect of this objective is to support the efficient acquisition and testing of innovative commercial products from legitimate suppliers, as well as the efficient production and fielding of the successfully tested innovative commercial products. This notice will be updated with the General Solicitation describing the solicitation process and evaluation approach. The solicitation will be open and proposals accepted on an ongoing basis. The Government intends to make awards in Fiscal Year 2020. Potential submitters are hereby advised of the following: 1. The solicitation for innovative commercial products in support of COVID-19 is not a guarantee that award and obligation of funds will be made. 2. The costs incurred by companies in the preparation and submission of their response to solicitations will not be paid by the government. 3. All potential recipients of CSOP awards must be registered in the System for Award Management (SAM) before the recipient is awarded the CSOP contract. (<https://www.sam.gov/SAM/>) The General Solicitation describing the solicitation process and evaluation approach will be

posted on or about Tuesday, April 14, 2020. All questions and comments regarding this special notice shall be submitted to email address [COVID19CSOP@HQ.DHS.GOV](mailto:COVID19CSOP@HQ.DHS.GOV).

Additional [beta.sam.gov](https://beta.sam.gov) information

Notice Id: ed7042324ab0452babb0e738812d1cd7

Source:

<https://beta.sam.gov/opp/ed7042324ab0452babb0e738812d1cd7/view>

Note: This link might not be valid after archive date below.

Archive Date: 04/29/2020

092560	<a href="#">COVID-19 Competitive Grant Program</a>	Pfizer Pharmaceuticals	22-May-2020	250,000.00 USD
--------	--	------------------------	-------------	----------------

Contact Name Derek Warnick

Contact Telephone 212-733-2323

Contact Email [derek.warnick@pfizer.com](mailto:derek.warnick@pfizer.com)

Sponsor Website <https://www.pfizer.com/>

Program URL <https://www.pfizer.com/purpose/medical-grants/process>

Deadline Dates (ALL) 22-May-2020

Synopsis

During this challenging time, Pfizer is committed to doing all they can to respond to the COVID-19 pandemic. They recognize the need for the rapid development of educational programs and trainings and the implementation of systemic best practices for COVID19 management. As part of their commitment, they are releasing this Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis.

SMARTS™ funding alerts are a service of [InfoEd Global](#)'s SPIN™ funding opportunities

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.



From: [research.libery@msm.edu](mailto:research.libery@msm.edu)  
 Subject: (GCO) COVID-19 Funding Opportunities (4/15/20)  
 Date: Wednesday, April 15, 2020 12:15:33 PM  
 Attachments: [COVID-19 SAGES infoEd.ans](#)

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date.

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



SPIN ID	Opportunity Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092608	<a href="#">COVID-19 Research Award</a>	Society of American Gastrointestinal and Endoscopic Surgeons		01-May-2020	15,000.00 USD
Contact Telephone	310-437-0544 x125				
Contact Email	<a href="mailto:research@sages.org">research@sages.org</a>				
Sponsor Website	<a href="https://www.sages.org/research/">https://www.sages.org/research/</a>				
Deadline Dates (ALL)	01-May-2020				
Synopsis	SAGES invites applications for research which focuses on one of several areas. All topics related to COVID-19 will be considered (e.g. Safety of Minimally Invasive Surgery & Endoscopy in COVID-19 positive patients, clinical considerations in surgical management of COVID-19 positive patients, evaluation of aerosol generating procedures, etc).				
077858	<a href="#">Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-18-935	None posted	Not Available
Contact Telephone	301-945-7573				
Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>				
Program URL	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html">https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html</a>				
Synopsis	The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.				
090204	<a href="#">Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-20-135	None posted	Not Available
Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>				
Program URL	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html</a>				
Synopsis	The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI. Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.				
071528	<a href="#">Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-18-591	None posted	Not Available
Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>				
Program URL	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html</a>				
Synopsis	National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section <a href="#">§ 1.2.11</a> of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.				

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.  
[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.